Actively Recruiting
Study of Immune Responses to Influenza and COVID-19 Vaccines in Adults with Lymphoma
Led by Emory University · Updated on 2026-07-06
200
Participants Needed
2
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the immune response to influenza and SARS-CoV2 vaccinations in patients with lymphoma. The goal is to better understand how the immune system changes in these patients during and after lymphoma treatment by measuring antibody levels and immune cell types over time compared to people without lymphoma. This research focuses on different lymphoma types and treatment effects on immunity. Participants receive a seasonal inactivated influenza vaccine by injection on day 0. Some also receive a SARS-CoV2 vaccine or booster doses. After vaccination, patients are monitored with follow-up visits on days 7, 28, 90, 180, and 365. These visits help evaluate the strength and duration of immune responses to the vaccines. During the study, researchers collect blood samples to measure antibody levels, virus-specific plasmablasts, and memory B cells. They assess seroprotection and seroconversion rates as primary outcomes, along with the timing and peak of immune responses. The study also tracks safety and overall immune changes for up to one year after vaccination.
CONDITIONS
Brief Title
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Research Team
A
Andres Chang, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here